reports
Ageas and BNP Paribas: Transparency notification
Ageas and BNP Paribas: Transparency notification Ageas and BNP Paribas: Transparency notification In accordance with the rules on financial transparency*, BNP Paribas has notified Ageas on 22 April 2024 that, on 19 April 2024, its interest has exceeded the legal threshold of 5% of the shares issued by Ageas. Its current shareholding stands at 6.65%. Reason for the notificationAcquisition or disposal of voting securities or voting rights Notification byA parent undertaking or a controlling person Persons subject to the notification requirementSee annex 1a D...
Ageas and Fosun: Transparency notification
Ageas and Fosun: Transparency notification Ageas and Fosun: Transparency notification In accordance with the rules on financial transparency*, Fosun has notified Ageas on 22 April 2024 that, on 19 April 2024, its interest has fallen below the legal threshold of 5% of the shares issued by Ageas. Its current shareholding stands at 4.64%. Reason for the notificationAcquisition or disposal of voting securities or voting rights Notification byA parent undertaking or a controlling person Persons subject to the notification requirementSee annex 1a. Date on which the threshold is crossed19 Apr...
Ageas et Fosun: Notification de transparence
Ageas et Fosun: Notification de transparence Ageas et Fosun: Notification de transparence Conformément aux règles de transparence financière*, Fosun a introduit le 22 avril 2024 une notification annonçant que, le 19 avril 2024, sa participation a franchi, à la baisse, le seuil légal de 5% des actions émises par Ageas et atteint 4,64%. Motif de la notificationAcquisition ou cession de titres conférant le droit de vote ou de droits de vote Notification parUne entreprise mère ou une personne détenant le controle Personne(s) tenue(s) à notificationVoir annexe 1a. Date de dépassement du seu...
Ageas en Fosun: Transparantiekennisgeving
Ageas en Fosun: Transparantiekennisgeving Ageas en Fosun: Transparantiekennisgeving Fosun informeerde Ageas op 22 april 2024, overeenkomstig de financiële transparantievereisten*, dat zijn belang op 19 april 2024 onder de wettelijke drempel van 5% van de door Ageas uitgegeven aandelen is gedaald en nu 4,64% bedraagt. Reden van de kennisgevingVerwerving of overdracht van stemrechtverlenende effecten of stemrechten Kennisgeving doorEen moederonderneming of een controlerende persoon Kennisgevingsplichtige perso(o)n(en)Zie bijlage 1a. Datum van drempeloverschrijding19 april 2024 Overschre...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Kristof Samoy
Ekopak WaaS flows steady, on track for 2028 objectives
We reworked our model following the FY23 results, the AR publication and a NDR with management. FY23 operational CF performance was solid as expected. 2024 capex guidance exceeded our expectations while NWC management was considerably better than forecast. The 2028 targets were reconfirmed and -dixit management- could be outperformed considerably. The GWE acquisition is fast tracking the international expansion of Ekopak, the pioneer in circular decentralised process water.
- Carole Braudeau
- Carole Braudeau
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
Ageas announces the Ordinary and Extraordinary General Meetings of Sha...
Ageas announces the Ordinary and Extraordinary General Meetings of Shareholders of ageas SA/NV Ageas announces the Ordinary and Extraordinary General Meetings of Shareholders of ageas SA/NV As the quorum required for the Extraordinary General Meeting of Shareholders of Wednesday 17 April 2024 will not be attained, ageas SA/NV is organising the Ordinary and Extraordinary Meetings of Shareholders (the "Meeting") on Wednesday 15 May 2024 at 10:30 a.m. The Meeting is being held at the Auditorium of AG Insurance, AG Campus, in 1000 Brussels, Rue du Pont Neuf 17. The general conditions for att...
Ageas annonce les Assemblées Générales Ordinaire et Extraordinaire des...
Ageas annonce les Assemblées Générales Ordinaire et Extraordinaire des Actionnaires d’ageas SA/NV Ageas annonce les Assemblées Générales Ordinaire et Extraordinaire des Actionnaires d’ageas SA/NV Étant donné que le quorum requis pour l’Assemblée Générale Extraordinaire des Actionnaires du mercredi 17 avril 2024 ne sera pas atteint, ageas SA/NV organisera les Assemblées Générales Ordinaire et Extraordinaire des Actionnaires (« l’Assemblée ») le mercredi 15 mai 2024 à 10h30. L’Assemblée se tiendra à l’Auditorium d’AG Insurance, AG Campus, Rue du Pont Neuf 17 à 1000 Bruxelles. Les modalités ...
Ageas kondigt de Gewone en Buitengewone Algemene Vergaderingen van Aan...
Ageas kondigt de Gewone en Buitengewone Algemene Vergaderingen van Aandeelhouders van ageas SA/NV aan Ageas kondigt de Gewone en Buitengewone Algemene Vergaderingen van Aandeelhouders van ageas SA/NV aan Aangezien het vereiste quorum voor de Buitengewone Algemene Vergadering van Aandeelhouders van woensdag 17 april 2024 niet zal worden bereikt, organiseert ageas SA/NV op woensdag 15 mei 2024 om 10u30 de Gewone en Buitengewone Algemene Vergaderingen van Aandeelhouders (de “Vergadering”). De Vergadering zal plaatsvinden in het Auditorium van AG Insurance, AG Campus, Nieuwbrug 17, te 1000 Bru...
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Lewi
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Sequana Medical FIRST LOOK: FY23 update comes with 90-day FDA letter f...
Sequana reported FY23 results with a cash position of € 2.6m (YE22: € 18.9m), which together with the € 3m convertible loan in February 2024 and € 11.5m equity placement in March 2024, provides a cash runway to end of 3Q24. The company is evaluating the feedback received last night in the 90-day letter from the FDA. Given the short timeframe, management is unable to provide more details on the FDA comments, and will update the market in due course. The company has a day-100 meeting scheduled wit...
Form 8.3 - The Vanguard Group, Inc.: Ageas SA/NV
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Ageas SA/NV 25-March-2024 / 14:22 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), se...
- Kristof Samoy
Ekopak FRN – feedback analyst call FY23 results
Ekopak delivered a good operational performance over FY23 in line with expectations and the outlook drawn for 2024 matches our revenue forecasts. Below are key take-aways from the analyst call with CEO and CFO. Our first read of the press release made to much of the statement on strategy finetuning: the company has no intentions to do acquisitions in the short term.
- Carole Braudeau
- Carole Braudeau
- Bruno Cavalier
- Jean Danjou
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
DAI DAIMLER AG
AGS AGEAS SA/NV
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
01913 PRADA S.P.A.
MONC MONCLER SPA
CFR COMPAGNIE FINANCIERE RICHEMONT SA
STM STMICROELECTRONICS NV
PHNX PHOENIX GROUP HOLDINGS PLC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.